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Abstract  
Objective: Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by 
mutations in the genes for LDL receptor (LDLR), apolipoprotein B (APOB) and Proprotein 
convertase subtilisin/kexin type9 (PCSK9). The purpose of the current investigation was to define 
the current spectrum of mutations causing FH in Israel.  
Methods: New families were collected through the MEDPED (Make Early Diagnosis Prevent 
Early Death) FH program. Molecular analysis of the LDLR, PCSK9 and APOB genes were done 
using High Resolution Melt and direct sequencing in 67 index cases. A 6-SNP LDL-C gene score 
calculation for polygenic hypercholesterolaemia was done using TaqMan genotyping.  
Results:  Mean serum cholesterol was 7.48±1.89mmol/L and the mean serum LDL-C was 
5.99±1.89mmol/L. Mutations in the LDLR and APOB gene were found in 24 cases (35.8%), with  
16 in LDLR, none in PCSK9 and one, p.(R3527Q)  in the APOB gene, which is the first APOB 
mutation carrier identified in the Israeli population. Of the LDLR mutations, two were novel; 
p.(E140A) and  a promoter variant, c.-191C>A. The c.2479G>A p.(V827I) in exon 17 of the 
LDLR gene was found in 8 patients (33.3% of the mutations) with modestly elevated LDL-C but 
also  in a compound heterozygous patient with a clinical homozygous FH phenotype, consistent 
with this being a “mild” FH-causing variant. A significantly higher 6-SNP LDL-C score was 
found in mutation-negative cases compared with a normal Caucasian cohort (p=0.03), confirming 
that polygenic inheritance of common LDL-C raising SNPs can produce an FH phenocopy. 
Conclusions: The results indicate a different spectrum of genetic causes of FH from that found 
previously, in concordance with the heterogeneous and changing origins of the Israeli population, 
and confirm that a polygenic cause is also contributing to the FH phenotype in Israel.  
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Background 
Familial Hypercholesterolaemia (FH, [OMIM #143890]) is a genetic disorder, inherited in an 
autosomal dominant fashion, characterized by the defective plasma clearance of low-density 
lipoprotein cholesterol (LDL-C), and may be caused by mutations in three genes: LDLR, APOB, 
and PCSK9 (1). A recessive form of FH due to mutations in LDLRAP1 is also known (2, 3) . FH 
is estimated to affect 1 in 230-250 individuals (4-6), and if untreated leads to premature coronary 
heart disease (CHD). Previous studies revealed that in several relatively isolated populations there 
is an increased frequency of FH (7-9). In some subpopulations, specific LDLR mutations were 
found to be common (10-17).  
 
Israel is comprised of many populations in which a founder effect has been well described, such 
as the Ashkenazi Jewish population, where the founder effect has been dated back to the 14th 
century (15, 18, 19).  Two decades ago we reported all identified mutations in the Israeli 
population causing FH (20).  The LDLR gene was systematically screened for mutations using 
methods available at the time such as single strand conformation polymorphism (SSCP) and 
denaturing gradient gel electrophoresis (DDGE). Families of patients with clinical characteristics 
of FH based on the Simone Broome criteria were recruited through the MED-PED (Make Early 
Diagnosis Prevent Early Death) FH program (21). Of the 192 families available for screening 15 
different mutations were found in 81 individuals (42%). The FH patients harboring these 15 
mutations originated from 10 countries (Israel, Hungary, Iraq, Russia, Lebanon, Lithuania, 
Morocco, Poland, Rumania and Syria). Since this publication, no systematic effort was made to 
expand our knowledge of FH-causing mutations in the Israeli population.  
 
We tested for the mutation in the index cases of 67 newly recruited Israeli FH families as part of 
the MED-PED project (21) using high-throughput  detection methods and Multiplex Ligation-
dependent Probe Amplification (MLPA) for exon deletions or insertions. However, it is well 
known that  about 60% of clinically diagnosed FH patients are mutation-negative (4), and it was 
hypothesized that FH can also be caused by an accumulation of LDL-C raising alleles each 
having small contributive effect (22). Using common variants affecting LDL-C concentration 
identified in the meta-analysis of genome-wide association studies by the Global Lipid Genetic 
Consortium (GLGC) (23), a gene score method based on twelve common LDL-C raising SNPs 
has been developed  (23) and subsequently refined to include only 6 SNPs (30). We therefore also 
genotyped our cohort for the effect of this 6-SNP score in our subjects.  
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Methods: 
Recruitment of FH patients and families  
Families of patients with clinical characteristics of FH are continuously recruited through the 
MED-PED (Make Early Diagnosis Prevent Early Death) FH program (21). Inclusion criteria for 
the index cases are mostly based on hypercholesterolemia with a plasma LDL-C level above the 
95th percentile for age and gender. Tendon xanthomas and history of premature (age under 60) 
ischemic heart disease in the patient or in a first-degree relative are recorded but are not required 
for recruitment. Biochemical determinations plasma triglyceride, total cholesterol and high 
density lipoprotein (HDL) cholesterol levels were determined using commercially available 
diagnostic kits (Boehringer Mannheim, Germany). Plasma LDL-C levels were calculated 
according to the Friedewald- Levy formula (24). For patients where untreated lipid levels were 
unavailable, the treated lipid levels have been adjusted for the recorded dose and type of statin 
being used (see table 2 in Supplementary data). 
Molecular Genetic Analysis 
High Resolution Melt (HRM): Oligonucleotide primers for PCR-HRM were designed (25) to 
cover the promoter and coding regions of LDLR (intron-exon junctions and up to 40 bp of the 
intron) together with a fragment of exon 26 of APOB to cover the area for common mutation 
p.(R3527Q), and exon 7 of PCSK9 to cover p.(D374Y). Exon 10 of LDLR was screened by two 
overlapping PCR fragments and exon 4 by four overlapping fragments. PCR and subsequent 
HRM were carried out (25) using the Rotor-Gene 6000 (Qiagen) using AccuMelt HRM 
SuperMix (from Quanta BioScience, DNA-saturating dye; SYTO 9) with 25 ng of gDNA and 4 
pmol per µl of each primer in a final volume of 10 μl. 
Restriction Fragment Length Polymorphism (RFLP): The samples were genotyped for common 
polymorphisms in LDLR by RFLP and their genotypes compared with the HRM result as 
described in Whittall et al. 2010 (25). Those with shifts due to polymorphism on the HRM were 
not examined further. However, samples without the polymorphism but with a shift were 
sequenced to find the cause of the melt temperature shift. The HRM-PCR products were used for 
digestion with the appropriate restriction enzyme (NEB (UK) Ltd. Hitchin, Herts) using 5 μl of 
HRM-PCR product and 3U of appropriate enzyme (supplementary Table S2) in a total volume of 
15 μl and run on a 1.5% agarose gel in 1xTBE buffer. 
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Sequence Analysis: HRM-PCR products PCR products that showed a shift in the melt profile and 
melt temperature were Sanger sequenced. The DNA purification was performed using Illustra 
GFX PCR DNA and Gel Band Purification Kit (from GE Healthcare). The same primers used for 
HRM-PCR were used for sequencing, which was performed by Source BioSciences, 
LifeSciences. 
Multiplex Ligation Dependent Probe Amplification (MLPA): To detect rearrangements within the 
coding sequence of LDLR, MLPA was performed according to the manufacturer’s protocol 
(MRC-Holland, Amsterdam, the Netherlands cat number P062-LDLR).  
In silico variant analysis: To predict the pathogenicity of novel LDLR variants, in silico mutation 
prediction tools, including Polymorphism Phenotyping version2 (PolyPhen-2) (26), Sorting 
Intolerant From Tolerant(SIFT) (27), Berkeley Drosophila Genome Project - Splice Site 
Prediction (BDGP) (28)and Mutation Taster (29) were used. The data from Exome Variant Server 
(http://evs.gs.washington.edu/EVS/) and UCL website https://grenada.lumc.nl/LOVD2/UCL-
Heart/home.php?select_db=LDLR were used to check if mutations were novel. Mutation 
nucleotide numbers were designated using the LDLR reference sequence reported 
(www.ucl.ac.uk/fh). Mutations were designated according to recommendations from Human 
Genome Variation Society (www.hgvs.org) 
LDL-C gene score calculations for polygenic hypercholesterolaemia:  To assess the polygenic 
cause of hypercholesterolaemia, patients were genotyped for 6 LDL-C raising SNPs based on 
recent findings (22, 23, 30).  KASPar PCR technique (Kbiosciences, UK Hoddesdon, Herts, UK) 
or TaqMan assays (Life Technologies, Carlsbad, California, US) and genotype calling for all 
assays was carried out using an automated system, the results of which were checked manually by 
study personnel using SNPviewer software. One SNP (rs4299376) could not be genotyped and a 
proxy was used instead (rs6544731). The LDL-C gene score was calculated using weighted. A 
group of 3,020 healthy volunteers (participants of the UK Whitehall II (WHII) study (31) was 
used for comparison.  
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Results:  
The cohort of 67 unrelated index patients (36 men and 31 women) with an average age of 45±15 
(youngest 10yrs, eldest 72yrs) were studied. A summary of the clinical characteristics and 
combined lipid data of the cohort is presented in Table 1. For patients where untreated lipid levels 
were unavailable, the treated lipid levels have been adjusted for the recorded dose and type of 
statin being used.  Overall, the mean serum total cholesterol was 7.48±1.89mmol/L (3.6 - 15.0 
mmol/L), and the mean serum LDL-cholesterol was 5.52±1.91 mmol/L (1.0 - 13.1 mmol/L). 15 
of the recruited patients have levels of untreated (or statin dose adjusted) LDL-C below the 
Simon Broome cut-off of 4.9mmol/l (supplementary Table 1) and are therefore strictly not 
subjects with a formal diagnosis of FH.  
Mutations of the LDLR and APOB gene were found in 24 patients which comprises 36% of the 
cohort (table 2, and Figure 1). If the 15 subjects who do not confirm to the SB diagnostic criteria 
are excluded, (ie with LDL-C <4.9mmol/l) the overall mutation detection rate increases to 23/52= 
46%. As expected, the mean total cholesterol and LDL-cholesterol (adjusted for statin use) was 
significantly higher in the group of patients with a mutation than in those without a mutation, 
(40% higher p= 0.02 for LDL-C and 32% higher p = 0.01 for TC). Among the twenty-four, 16 
different LDLR mutations were found of which two were novel, and the p.(R3527Q) APOB 
mutation was also identified. This is the first reported APOB mutation carrier  identified in the 
Israeli population. No PCSK9 mutations were identified. Two mutations, p.(G219del)  and 
p.(D167H), which are founder mutations in Ashkenazi and Sephardic Jewish ethnic group 
respectively, were observed in two probands (Is681 and Is687) (20). Three probands (IS 537, 
IS544, and IS 595) were found to carry a 10 base pair deletion (c.1570_1579del) in exon 10 of 
LDLR which leads to a frameshift change ending in a stop codon after twenty-one residues. This 
deletion, which was first seen in a Jewish Iraqi FH patient (20) (and was incorrectly described as 
a 9bp deletion), occurs in the EGF precursor homology domain of the LDLR and is predicted to 
be pathogenic.  
 Two novel LDLR mutations were identified: c.-191C>A in the promoter region, and p.(E140A), 
in exon 4. The relatives of these index cases were recruited to provide evidence for segregation of 
the mutations with elevated LDL-C (figure 2). In the pedigree shown in Figure 2A, the proband is 
clinically homozygous with LDL-C of 11.1mmol/l and is a compound heterozygote for both 
LDLR c.1570-1579del and c.-191C>A.   The two offspring both carry the c.-191C>A mutation 
and have LDL-C levels in the range of heterozygous FH. In Figure 2B, for the p.(E140A) 
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mutation, the co-segregation of the mutation with elevated LDL-C levels is shown in a three 
generation family.   Two additional families were studied. Pedigree 2C is of a Druze family with 
the exons 7-14del mutation showing segregation of the mutation with the trait with 18 family 
members carrying the deletion and also having elevated TC/LDL-C. In the pedigree shown in 
Figure D the proband has passed the p.(C121S) allele to his daughter who has elevated LDL-C 
levels.   
p.(V827I) was found in 8 individuals in our cohort. This variant has been reported before as 
causing FH (32, 33). LDL-C levels in these subjects were 4.1, 4.8, 4.91, 5.38, 5.72 5.9, 6.2 and 
6.5mmol/l (supplementary Table 1), with a mean of 5.4mmol/l suggesting a mild mutation. 
However this mutation was found as a compound heterozygous mutation with p.(E140A) (above) 
with a clinical homozygous FH phenotype. To explore this further, we genotyped all the Israeli 
cohort for six common LDL-C raising SNPs previously reported, to see if polygenes could 
explain the increased LDL-C concentration in the no mutation group as well as the p.(V827I) 
group. Figure 3 presents the mean gene scores in the Israeli mutation-positive and mutation-
negative groups, compared with those of healthy UK WHII cohort. The highest mean 6 SNP 
score was observed in the FH mutation negative group compared to the UK healthy control group 
(0.682 (0.14) vs 0.632 (0.22), p=0.03). We have  estimated that FH mutation-negative patients 
who have the SNP score above the top quartile of the score distribution have a more than 95% 
probability of having their hypercholesterolaemia due to a polygenic cause (30). Based on the 
WHII population 6 SNPs  score top quartile (=0.51), in our study 36 out of the 41 mutation 
negative samples with sufficient genotyping data (87.8%) have a score above the cutoff, 
compatible with their hypercholesterolaemia having a polygenic and not a monogenic etiology. 
By contrast, both the FH mutation positive group and the individuals who carry the LDLR 
p.(V827I) variant had a similar intermediate  mean score (0.656 (0.15) and 0.648 (0.14) 
respectively, p = 0.9), not significantly higher than the control group (p=0.55).    However, six out 
of the eight p.(V827I) carriers (75%)  had a 6 SNP score above the top quartile cutoff. This 
finding suggests that the effect of the p.(V827I) variant on its own is  insufficient to cause the full 
phenotype of FH, without an additional “polygenic” contribution.  
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Discussion.  
The molecular detection and identification of mutant LDL receptor alleles is important from 
several aspects. First, it provides the only definitive diagnosis of FH. Second, the correct 
estimation of the prevalence of FH in a specific population is only possible through screening for 
the actual molecular defects. Third, it enables a high rate (50%) of screening success of  first 
degree relatives of index cases, enabling early diagnosis and prevention of cardiovascular disease 
(34).  The Israeli population is very heterogeneous, consisting of a multitude of origin groups. In 
1996 we published the first paper on  the systematic mutation screening for FH patients (20). In 
the current paper we report the results of mutation systematic screening of 67 new FH index cases 
recruited through the MED-PED project.  
Our results show that the FH mutation spectrum in Israel has changed considerably over the last 
20 years. We identified 16 different LDLR mutations and the first reported APOB p.R35227Q 
carrier in the Israeli population, with an overall mutation detection rate of 36%, rising to 46% if 
we apply the strict LDL-C cut-off suggested by the Simon Broome criteria. Previously (20), we 
reported on mutation detection in 95 index cases, and detected 15 different mutations in 
49 cases (detection rate 52%). Three mutations explained 34% of index cases, (Gdel219 
(FH-Lithuania), D1687H (FH-Sephardic), and C681X (Lebanese)), and these were 
regarded as founder mutations in the three respective groups. Here we found only one 
individual with Gdel219 and one D168H and none with C681X, with the three most 
common mutations seen earlier now only explaining 8% of mutation carriers (2/24). We found 
two novel LDLR mutations. One variant in exon 4 p.(E140A), and a promoter variant, c.-
191C>A, have not been seen in published literature, but both showed co-segregation compatible 
with being FH-causing. We also noted a probably novel major deletion of exons 7-14, found in a 
pedigree of Druze ancestry, although it is not possible to be absolutely certain that the deletion 
seen here is different from similar deletions reported previously (35) since break points have not 
been established. We found that a mutation p.(V827I), previously reported in subjects of Russian 
origin Russia (33),   to be the most common variant in our sample explaining 8/24 or 33% of the 
detected mutations. This variant was not seen previously in Israel and is likely to result from 
recent changes in the population demographics. In the group where no mutation was identified 
there is highly likely to be a polygenic cause of their elevated LDL-C and FH diagnosis, based on 
a 6-SNP gene score.  
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Pathogenicity of novel mutations 
Individual Is556-03 is carrying the novel mutation, p.(E140A).  It is predicted to be damaging by 
both PolyPhen™, SIFT™ and Mutation Taster™ and the mutation segregates with elevated LDL-
C levels. Glutamic acid140 is present in the ligand-binding domain of the LDL-receptor. A 
different variant substitution at position c.419, an A to G base change leading to a glutamic acid 
to glycine substitution, was reported as novel in 2001 by Fouchier and colleagues in Netherland 
FH patients (36). Comparative proteogenomics analysis across several species show a high level 
of conservation of Glutamic acid at position p.140. Thus, p.(E140A) is very likely to be a 
mutation.  
Individual Is 537 is carrying c.-191C>A, in the promoter region of the LDLR. The variant is 
located within the repeat 1 (RP1) sequence which has been shown to be a binding site for Sterol 
Regulatory Element Binding Protein (SREBP) and is therefore very likely to be FH causing (37). 
Is537 is carrying another, well described mutation, (c.1570_1579del). To better define if c.-
191C>A causes FH, we genotyped several other relatives in the Is 537 pedigree. The index case 
is a compound heterozygote and has LDL-C levels in the range of homozygous FH. Her two 
children inherited only the c.-191C>A mutation, and have LDL-C levels in the range of 
heterozygote FH. Thus, it is likely that both mutations contribute to the compound heterozygote 
of the index case.  
Individual Is697 carries a deletion of exons 7-14 as shown by MLPA analysis. We expanded the 
pedigree and demonstrated perfect segregation of the deletion with hypercholesterolemia.  Thus, 
this major deletion seems to be a new LDLR mutation within the Druze population.  
We also tested the available relatives of individual Is660 who is carrying the mutation p.(C121S) 
first reported in a UK patient in 2013 (57) but where little clinical data is reported. PolyPhen™, 
™ and MutationTaster™ all predict the variant to be damaging and disease causing (Table 3) (26, 
27, 29). This mutation occurs in the ligand binding domain of the LDL-receptor, a cysteine repeat 
rich region that is important for disulphide bridge formation. The family tree could only be 
extended to one more individual carrying the mutation with a phenotype of FH.  
p.(V827I) Variant:  
The c.2479G>A p.(V827I) in exon 17 of the LDLR gene was found in 8 patients and constituted 
33.3% of the mutations identified in the Israeli FH cohort. If the eight carriers of the p.(V827I) 
variant were excluded from the mutation positive patient group, the overall mutation 
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detection rate would fall from 35.8% to 23.8%. It was first found in an American 
homozygous FH patient by Hobbs and colleagues (5) as FH-New York 5. This homozygous FH 
patient was later discovered to be a compound heterozygote, as the patient was seen to have 
another LDLR mutation. In 2005, Zakharova and colleagues identified the same variant in one 
family in St. Petersburg, Russia (33). This change has also been identified twice as potentially 
deleterious among 81 healthy individuals randomly assigned for exome sequencing (32). This 
variant was not identified in the Israeli FH patient samples examined in 1996, and the high 
frequency of this variant in the current samples studied is likely to reflect the recent immigration 
to Israel of individuals from Russia.  
This substitution occurs in the tetrameric consensus sequence NPxY (where x is any amino acid) 
that plays a major role in the coated pit-mediated internalization of the LDL-receptor via 
interaction with the protein autosomal recessive hypercholesterolaemia (ARH) (38, 39). The 
NPVY sequence in the cytoplasmic domain of the LDL-receptor is a major site of recognition for 
incorporation into clathrin-coated pits. The stringency at the third position (position p.827 “V”) in 
this tetrameric sequence, is not as marked as that seen at the other three positions. Reduction in 
LDL-C cellular  internalization index  to approximately 65% of control values was seen when the 
valine of the NPVY sequence was replaced with an alanine or a cysteine (38). However, data 
from the UCSC Genome browser conservation tab and PolyPhen’s sequence alignment show the 
valine of the tetrameric sequence to be highly conserved across species.  
One of the carriers of p.(V827I) is a compound heterozygote, and carries both p.(V827I) and 
p.(E140A) and has the phenotype of an FH homozygote.  The LDL-C SNP score analysis showed 
that individuals who carry the variant have a similar SNP higher score to those who inherited 
other LDLR FH-causing mutations. However, one fact which suggests that the p.(V827I) 
variant is not FH-causing is that it is seen at a frequency of 0.00076 (92 carriers/121,374 
alleles sequenced) in the ExAC database http://exac.broadinstitute.org/variant/19-
11240278-G-A. While it is thus one of the more common mis-sense variants in the LDLR 
gene, several other FH-causing variants are found at similar frequency (eg p.(G324S) 
present in 140/120384 for a frequency of 0.0012), with the APOB variant p.(R3527W) is 
present in 28/121182 alleles for a frequency of 0.00023. While a recently-recruited 
sample of normolipidaemic Israeli subjects would be useful to determine the frequency of 
V827I in healthy subjects, this is beyond the scope of the current study. Overall the 
published data and this study suggests that the p.(V827I) variant is a mild FH-causing variant. 
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Polygenic Familial Hypercholesterolaemia:  
We genotyped the Israeli cohort for the 6 common LDL-C raising SNPs, based on the score 
suggested by Talmud et al and refined by Futema et al (22, 30). Effects were similar  to those 
published previously, with a found a significantly higher score in mutation-negative cases 
compared with the normal Caucasian cohort, with the score suggesting that a polygenic etiology 
is the likely explanation for the hypercholesterolaemia in ~90% of the mutation negative subjects. 
. This score was validated before in  several European mutation negative FH patient cohorts and 
found to be consistently  higher than in the UK general Caucasian population reference group, 
and with no significant difference in score between the various FH cohorts (30). Since the 
patients studied here are of the same ethnic background as the UK sample used previously, the 
comparison is unlikely to be confounded by ethnicity.  In such “polygenic 
hypercholesterolaemia” patients, first degree relatives are less likely to have high LDL-C than in 
mutation-positive patients. Thus, for successful screening of first degree relatives of FH patients, 
it is likely to be cost effective to ascertain that the index individual carries a known FH-causing 
mutation. By contrast, whole genome or exome sequencing in the low SNP score no-mutation 
patients may reveal novel genetic causes of FH. 
Our study has some limitations. While we have previously demonstrated that HRM is a 
sensitive and specific technique (25) for mutation detection in FH patients, we 
acknowledge that Next Generation Sequencing (NGS) is now the preferred method of 
choice for molecular diagnosis, but this work was commenced in 2013 when such 
methods were not widely available and NGS is still an expensive technique and beyond 
the funds available for this research project. The overall mutation detection rate in our 
sample is relatively low compared with other similar published cohorts. (40-42), although 
similar mutation detection rates were recently reported in Korea (43). This may be 
because our inclusion criteria were less stringent than in other studies resulting in fewer 
“monogenic” FH patients and a lower mutation detection rate, and exclusion of those 
with LDL-C below the diagnostic threshold of 4.5mmol/l increased the mutation 
detection rate to 46%. This may, however, also be because of population differences in 
FH mutation prevalence. Also, while we screened the regions of the PCSK9 and APOB 
genes known to contain pathogenic mutations (25), it is possible that a small proportion 
of patients may have mutations in the exons not covered here. While pathogenic variants 
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in other regions of APOB have been reported (44) these are very rare. Similarly, gain-of-
function FH causing mutations in PCSK9 are also rare, for example explaining less than 
2% of FH patients in the UK, and none have been found in Israel. We therefore estimate 
that complete coverage of these two genes may at best have increased the overall 
detection rate by 2-3%.   Finally, a limitation of the conclusion that the mean LDL-SNP 
score in the no-mutation subjects is significantly higher than in healthy controls is that we 
do not have a comparison group of healthy Israeli subjects and have used a sample of UK 
healthy controls. Since both groups are of European origin and both are white Caucasians 
we believe it is unlikely that the result is a false positive, and the mean score in the 
mutation positive subjects is similar to that in the UK healthy group as has been reported 
for other mutation positive patients (22, 30).     
 
Conclusion 
The FH mutation spectrum in Israel has changed very considerably over the last 20 years. While  
a sample of 67 patients attending a single lipid clinic in Jerusalem will not be fully  
representative of all Israeli FH subjects, we clearly show that the current mutation 
distribution is very different compared to the 1996 study. It is likely that a much larger 
sample would find a wider range of mutations (both reported and novel), and also 
possible that patients from lipid clinics in other metropolitan centres may have a different 
mixture of Ashkenaz, Sephardic and Palestinian-Arab subjects. (RONEN IS THIS OK??) 
The most common mutation in the FH patients was p.(V827I) which appears to be of mild effect. 
In the vast majority of subjects were no mutation could be identified, there is likely to be a 
polygenic cause of their elevated LDL-C and FH diagnosis. These data can help design a future 
strategy for early screening for FH in our population.  
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Table 1. Showing the combined clinical characteristics (Mean +SD) of the Israeli FH cohort. 
S.D, standard deviation; TG, triglycerides; TC, total cholesterol; +ves/-ves, positives/negatives. 
 
 
 
 
 
  
  
All FH Patients 
(n=67) 
Patients with 
mutation(n=2
4) 
Patients 
without 
mutation(n=43) 
 Difference 
b/w 
mutation 
+ves & -ves 
P-value 
Age years  45±15 41±15 47±14 0.15 
Sex  Female n (%) 36(53.7) 13(54.2) 23(53.5) 
0.96 
 
Male     n (%) 31(46.3) 11(45.8) 20(46.5) 
HDL-C 
mmol/L 
 
1.20 ± 0.28 1.14 ± 0.31 1.23 ± 0.26 0.18 
TG 1.62 ± 0.60 1.67  ± 0.66 1.59 ± 0.57 0.59 
LDL-C 5.52 ± 1.91 6.00 ± 1.89 5.26 ± 1.89 0.12 
TC 7.48 ± 1.89 7.90 ± 1.88 7.25 ± 1.87 0.18 
On Statin  n (%) 18(26.9) 7(29.2) 11(25.6)  
LDL-C before 
treat 
 5.99 ± 1.89 7.27 ± 1.60 5.18 ± 1.72 0.02 
  (n=18) (n=7) (n=11)  
LDL-C Paired t-test 
before/after treatment 
 0.001 0.000 significant 
TC before 
treat 
 8.64 ± 2.20 10.16 ± 1.76 7.68 ± 1.93 0.01 
  (n=18) (n=7) (n=11)  
TC Paired t-test before/after 
treatment 
 0.001 0.000 significant 
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Table 2. Nucleotide changes identified by HRM, RFLP and sequencing in the LDLR and APOB gene among 67 Israeli FH patients 
  
 
Sex 
 
Age 
TC HDL LDL 
 
Statin 
Identified variant 
Patient 
ID 
(mmol/l) (mmol/l) (mmol/l) 
AA change 
(variant 1) Nucleotide change 
AA change 
(variant 2) Nucleotide change 
Is694 F 38 9.2 1.2 6.5 N p.(V827I) c.2479G>A  
 Is537 F 33 12.67 0.91 11.35 N n/a c.-191C>A p.(V524Ffs*21) c.1570_1579del 
Is522 F 50 5.97 1.97 3.41 Y p.(V827I) c.2479G>A   
Is556-03 F 25 13 0.74 11.3 N p.(E140A) c.419A>C p.(V827I) c.2479G>A 
Is544 F 37 6.7 1.24 5.12 Y p.(V524Ffs*21)*  c.1570_1579del   
Is579 M 46 7.5 0.78 5.90 N p.(V827I) c.2479G>A   
Is564 F 45 5.82 1.68 3.52 Y p.(G314R) c.940G>A   
Is589 F 35 8.56 0.88 6.72 N n/a c.-156C>T   
Is634 M 39 7.27 1.24 4.91 N p.(V827I) c.2479G>A   
Is628 M 62 6.13 1.03 4.40 Y p.(V827I) c.2479G>A   
Is678 M 60 6.8 0.72 4.8 N p.(V827I) c.2479G>A   
Is636 F 29 7.32 1.47 5.38 N p.(V827I) c.2479G>A  
 Is595 F 43 9.62 1.09 7.78 N p.(V524Ffs*21)* c.1570_1579del  
 Is588 M 10 9.26 1.24 7.29 N p.(P685L) c.2054C>T  
 Is662 F 32 5.2 1.16 3.65 Y APOB p.(R3527Q) c.10580G>A  
 Is671 M 25 7.81 1.03 6.10 N p.(G207=) c.621C>T  
 Is660 F 72 6.9 1.06 5.20 Y p.(C121S) c.362G>C  
 Is637 M 55 5.07 0.75 3.41 Y p.(V797M) c.2389G>A   
Is658 F 54 7.96 1.06 6.21 Y p.(A431T) c.1291G>A  
 Is681 M 23 6.88 1.01 5.30 Y p.(G219del)* c.654_656del  
 Is685 F 31 6.9 1.14 5.12 N p.(R416W) c.1246C>T  
 Is699 M 71 4.94 0.91 3.34 Y p.(E277K) c.829G>A  
 Is697 M 49 4.76 1.09 2.95 Y exons 7-14 del c.941-?_2140+?del  
 Is687 M 30 5.43 1.11 3.96 Y p.(D168H)* c.502G>C  
 TC, total serum cholesterol; HDL, high-density lipoprotein; LDL, Low-density lipoprotein; AA, amino acid 
*Mutation previously reported in Israeli FH patients (20).  
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Table 3. Nucleotide changes identified in the Israeli FH cohort and in silico prediction of their pathogenicity.   
†Percentage of all detected LDLR and APOB mutation ‡Reference shown is for population of first discovery   * abbreviations are according to the ISO 3166 standard for country codes and their subdivisions available at 
http://www.iso.org/iso/home/standards/country_codes.htm and details of full references for each variant is available on the UCL LDLR database https://grenada.lumc.nl/LOVD2/UCL-Heart/home.php?select_db=LDLR.  
     
Protein Prediction                 Splice Prediction  
No. of patients 
with the 
mutation (%)† 
Overall/in silico 
Pathogenic 
Prediction 
Reference‡ 
No. AA Change Nucleotide change Location 
Occurrence in 
other 
populations* 
PolyPhen™ 
Prediction  
SIFT™ 
Prediction  
Mutation 
T@ster 
Prediction  
BDGP 
Human 
Splice 
Finder (%) 
 
LDLR Promoter variant 
     
    
1 c.-191C>A 
 
Prom Novel 
    
23.2 1(4.2) Probably New 
2 c.-156C>T 
 
Prom DE 
    
10.4 1(4.2) Probably (53) 
 
LDLR missense variant 
     
    
3 p.(C121S) c.362G>C Exon 4 GB 
Probably 
damaging 
Damaging Disease causing 
 
 1(4.2) Yes (57) 
4 p.(D168H) c.502G>C Exon 4 IL, NL 
Probably 
damaging 
Damaging Disease causing 
 
 1(4.2) Yes (55) 
5 p.(E140A) c.419A>C Exon 4 Novel 
Probably 
damaging 
Damaging Disease causing 
 
 1(4.2) Yes New 
6 p.(E277K) c.829G>A Exon 6 
CU,SE,ES 
IN,TR 
Benign Tolerated Disease causing 
 
 1(4.2) Yes (45) 
7 p.(R416W) c.1246C>T Exon 9 
GB,NO,AT 
DE, NL 
Probably 
damaging 
Damaging Disease causing 
 
 1(4.2) Yes (46) 
8 p.(A431T) c.1291G>A Exon 9 
DZ,JP,NL 
CN, GR 
Probably 
damaging 
Damaging Disease causing 
 
 1(4.2) Yes (47) 
9 p.(P685L) c.2054C>T Exon 14 
ZM, GB, JP 
NL, CN 
Probably 
damaging 
Damaging Disease causing 
 
 1(4.2) Yes (48) 
10 p.(V827I) c.2479G>A Exon 17 
US, NL 
RU, DK 
Probably 
damaging 
Tolerated Disease causing 
 
 8(33.3) Uncertain (5) 
 
Variants predicted to affect splicing 
     
    
11 p.(G207=) c.621C>T Exon 4 NL n/a Tolerated Disease causing 
C = 0 
T = 0.99 
C = 65.5 
T = 92.3 
1(4.2) Yes (54) 
12 p.(G314R) c.940G>A Exon  6 AT Benign Tolerated Disease causing 
G = 0.98 
A = 0.70 
G = 45.4 
A = 74.3 
1(4.2) Yes (58) 
13 p.(V797M) c.2389G>A Exon 16 
CU,CN,NL 
FR, MX 
Benign Tolerated Disease causing 
G = 1.00 
A = 0.89 
G = 57.5 
A = 86.4 
1(4.2) Yes (45) 
 
LDLR In-frame deletion 
     
    
14 G219del c.654_656del3 Exon 4 
US,GB,IL 
DE,PL 
n/a n/a Disease causing 
 
 1(4.2) Yes (47) 
 LDLR Large rearrangement          
15 Exons 7-14 del c.941-?_2140+?del Exons 4-14 Novel n/a n/a n/a   1(4.2) n/a New 
 
LDLR frame-shift mutation 
     
    
16 p.(V524Ffs*21) c.1570_1579del Exon 10 IL n/a n/a Disease causing 
 
 3(12.5) Yes (20) 
 
APOB variant 
     
    
17 p.(R3527Q) 
c.10580G>A 
Exon 26 Caucasian 
Probably 
damaging 
Damaging Disease causing 
 
 
1(4.2) Yes (56) 
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Figure 1 Diagrammatic representation of the LDLR annotated with identified sequence changes 
in the Israeli FH cohort. The stars indicate novel variants  
Figure 2:  Four pedigrees with FH. Pedigree A shows that the proband is clinically homozygous 
for both LDLR del 1570-1579 and the novel LDLR Cc.-191C>A. Pedigree B showing segregation 
of the novel p.(E140A) mutation. Pedigree C is of a Druze family with Ex. 7-14 del mutation 
showing segregation of the mutation with the trait. Pedigree D of a small family segregating the 
LDLR p.(C121S) mutation 
Figure 3: Boxplot of the 6 SNP LDL-C score in FH patients by a presence of an FH mutation in 
comparison to the WHII control cohort. Only samples where all 6 SNP genotypes were obtained 
are included.  The highest mean (SD) 6 SNP score was observed in the FH mutation negative 
group (0.682 (0.14)), which was significantly lower (p=0.03) than the control group (0.632 (0.22). 
Individuals who carry the LDLR p.(V827I) variant have intermediate mean score (0.648 (0.14)), 
not different from other mutation carriers (p=0.9). 
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